[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 34 of about 34
1. Minig L, Farnetano G, Peiretti M, Roviglione G, Zanagnolo V, Pelosi G, Landoni F: Poorly differentiated synovial sarcoma of the vagina: a case report and a clinical literature review. Ecancermedicalscience; 2008;2:99

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Poorly differentiated synovial sarcoma of the vagina: a case report and a clinical literature review.
  • Synovial sarcomas (SS) account for 5-10% of soft-tissue sarcomas and typically arise in the para-articular regions of adolescents and young adults.
  • Here, we present a first clinical literature report of a patient with an SS arising from the vaginal wall.
  • A 40-year-old patient who presented a necrotic polypoid lesion, measuring 50 mm and extending from the external urethral meatus to the middle part of the anterior vaginal wall.
  • The patient, prior to the radical surgery, received neoadjuvant chemotherapy (ifosfamide and epirubicin) for three cycles.
  • She underwent post-operative external radiotherapy and brachytherapy (50 Gy) due to close margins (<1 mm) in the pathologic specimen.
  • She relapsed 11 and 16 months later with lung metastases, which, both times, were successfully removed by surgical resection.
  • At 24 months from diagnosis, the patient is alive without further evidence of disease.
  • In summary, in the presence of unfavourable prognostic factors, neoadjuvant chemotherapy could be the primary approach to reduce the tumour size and the risk of distant micro-metastases allowing a less aggressive radical surgery if the tumour is located in a non-extremity site.
  • In fact, in our patient we obtained a complete clinical control in the pelvis, avoiding pelvic exenteration with neoadjuvant chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22275979.001).
  • [ISSN] 1754-6605
  • [Journal-full-title] Ecancermedicalscience
  • [ISO-abbreviation] Ecancermedicalscience
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3234049
  •  go-up   go-down


2. Hayashi M, Tsuchiya H, Yamamoto N, Karita M, Shirai T, Nishida H, Takeuchi A, Tomita K: Caffeine-potentiated chemotherapy for metastatic carcinoma and lymphoma of bone and soft tissue. Anticancer Res; 2005 May-Jun;25(3c):2399-405
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Caffeine-potentiated chemotherapy for metastatic carcinoma and lymphoma of bone and soft tissue.
  • BACKGROUND: We previously reported that caffeine-potentiated chemotherapy induced significantly good response in patients with musculoskeletal sarcomas.
  • In that series, patients with metastatic carcinoma or lymphoma were treated with caffeine-potentiated chemotherapy.
  • PATIENTS AND METHODS: Five patients with metastatic carcinoma or lymphoma were treated with caffeine-potentiated chemotherapy.
  • RESULTS: Primary tumors were diagnosed as breast cancer, adenocarcinoma of the lung, clear cell adenocarcinoma of the vagina, diffuse large B-cell lymphoma and gastric cancer.
  • Good responses (gross tumor shrinkage >30%, or histologically >90% necrosis) to chemotherapy were seen in all five patients.
  • Survival time was >1 year in all patients, and three out of five patients presented no evidence of local recurrence or metastasis at the final follow-up.
  • CONCLUSION: Caffeine-potentiated chemotherapy may be of benefit for malignant tumors other than musculoskeletal sarcoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / drug therapy. Caffeine / pharmacology. Carcinoma / drug therapy. Lymphoma, B-Cell / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Aged. Breast Neoplasms / drug therapy. Breast Neoplasms / pathology. Drug Synergism. Female. Humans. Lung Neoplasms / drug therapy. Lung Neoplasms / pathology. Male. Middle Aged. Stomach Neoplasms / drug therapy. Stomach Neoplasms / pathology. Vaginal Neoplasms / drug therapy. Vaginal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Caffeine.
  • Hazardous Substances Data Bank. CAFFEINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16080466.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 3G6A5W338E / Caffeine
  •  go-up   go-down


3. Gangopadhyay M, Raha K, Sinha SK, De A, Bera P, Pati S: Endodermal sinus tumor of the vagina in children: a report of two cases. Indian J Pathol Microbiol; 2009 Jul-Sep;52(3):403-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endodermal sinus tumor of the vagina in children: a report of two cases.
  • Malignant tumors of the vagina in infants and children are rare, with primary germ cell tumor (endodermal sinus tumor [EST]) being rarer, which carries a dismal prognosis.
  • Two cases of EST of the vagina in infants aged 9 and 17 months are reported.
  • Both the patients presented with bleeding per vagina and clinically and by ultrasonography were diagnosed as sarcoma botryoides.
  • One patient aged 9 months expired 2 months after receiving chemotherapy.
  • The other, aged 17 months, was given chemotherapy followed by surgery with reduction of the AFP levels.
  • [MeSH-major] Endodermal Sinus Tumor / diagnosis. Endodermal Sinus Tumor / pathology. Vaginal Neoplasms / diagnosis. Vaginal Neoplasms / pathology
  • [MeSH-minor] Fatal Outcome. Female. Hemorrhage / etiology. Histocytochemistry. Humans. Infant. Treatment Outcome. Vagina / pathology. alpha-Fetoproteins / analysis

  • MedlinePlus Health Information. consumer health - Vaginal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19679975.001).
  • [ISSN] 0974-5130
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / alpha-Fetoproteins
  •  go-up   go-down


Advertisement
4. Skeete DH, Cesar-Rittenberg P, Jong R, Murray SK, Colgan TJ: Myeloid sarcoma of the vagina: a report of 2 cases. J Low Genit Tract Dis; 2010 Apr;14(2):136-41
MedlinePlus Health Information. consumer health - Vaginal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myeloid sarcoma of the vagina: a report of 2 cases.
  • OBJECTIVE: To describe 2 cases of myeloid sarcoma of the vagina, in a patient without a history of acute myeloid leukemia (AML) and in another whose condition was previously diagnosed with AML.
  • MATERIALS AND METHODS: The clinical histories of 2 patients whose conditions were diagnosed with myeloid sarcoma of the vagina were obtained from their medical records.
  • RESULTS: Case 1: A 77-year-old woman with no systemic illnesses presented with a vaginal lump.
  • The histopathologic specimen was evaluated on routine and immunohistochemical stains, and myeloid sarcoma was diagnosed after extensive immunohistochemical analysis.
  • She developed extensive myeloid sarcoma of the skin and AML 4.5 months later; she died 2 weeks later, 5 months after the initial presentation.
  • Physical findings revealed large masses in the vagina and rectovaginal septum, which were confirmed as myeloid sarcoma after biopsy and histologic examination.
  • The patient was treated with pelvic/vaginal radiation.
  • Five months later, she had another leukemic relapse and died within 1 day of palliative chemotherapy.
  • CONCLUSIONS: Myeloid sarcoma of the vagina is extremely rare.
  • [MeSH-major] Sarcoma, Myeloid / diagnosis. Vagina / pathology. Vaginal Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Myeloid sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20354424.001).
  • [ISSN] 1526-0976
  • [Journal-full-title] Journal of lower genital tract disease
  • [ISO-abbreviation] J Low Genit Tract Dis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / SAGE protein, human
  •  go-up   go-down


5. Farley J, O'Boyle JD, Heaton J, Remmenga S: Extraosseous Ewing sarcoma of the vagina. Obstet Gynecol; 2000 Nov;96(5 Pt 2):832-4
MedlinePlus Health Information. consumer health - Vaginal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extraosseous Ewing sarcoma of the vagina.
  • BACKGROUND: Ewing sarcoma is a highly malignant childhood bone neoplasm.
  • Extraosseous presentations of Ewing sarcomas include the trunk, extremities, uterus, cervix, and vagina.
  • CASE: A 35-year-old woman, gravida 3, para 3, presented with a painless vaginal mass.
  • After surgical excision, pathology results diagnosed an extraosseous Ewing sarcoma.
  • Chemotherapy was given, followed by external beam and vaginal intracavitary brachytherapy, then more chemotherapy.
  • After 48 months post-treatment, there is no clinical evidence of recurrence.
  • CONCLUSION: Although rare, Ewing sarcoma can present as a vaginal mass.
  • [MeSH-major] Sarcoma, Ewing / pathology. Vaginal Neoplasms / pathology

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11094227.001).
  • [ISSN] 0029-7844
  • [Journal-full-title] Obstetrics and gynecology
  • [ISO-abbreviation] Obstet Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


6. Ferenschild FT, Vermaas M, Verhoef C, Ansink AC, Kirkels WJ, Eggermont AM, de Wilt JH: Total pelvic exenteration for primary and recurrent malignancies. World J Surg; 2009 Jul;33(7):1502-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Total pelvic exenteration (TPE) is an exenterative operation for these advanced tumors and involves en bloc resection of the rectum, bladder, and internal genital organs (prostate/seminal vesicles or uterus, ovaries and/or vagina).
  • METHODS: Between 1994 and 2008, a TPE was performed in 69 patients with pelvic cancer; 48 with rectal cancer (32 primary and 16 recurrent), 14 with cervical cancer (1 primary and 13 recurrent), 5 with sarcoma (3 primary and 2 recurrent), 1 with primary vaginal, and 1 with recurrent endometrial carcinoma.
  • Ten patients were treated with neoadjuvant chemotherapy and 66 patients with preoperative radiotherapy to induce down-staging.
  • Five-year local control for primary locally advanced rectal cancer, recurrent rectal cancer, and cervical cancer was 89%, 38%, and 64%, respectively.
  • Overall survival after 5 years for primary locally advanced rectal cancer, recurrent rectal cancer, and cervical cancer was 66%, 8%, and 45%.
  • CONCLUSIONS: Total pelvic exenteration is accompanied with considerable morbidity, but good local control and acceptable overall survival justifies the use of this extensive surgical technique in most patients, especially patients with primary locally advanced rectal cancer and recurrent cervical cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Surg Oncol. 2003 Nov;29(9):743-6 [14602493.001]
  • [Cites] Dig Surg. 2003;20(3):192-9; discussion 200 [12759498.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Jan 1;58(1):106-12 [14697427.001]
  • [Cites] Gynecol Oncol. 2004 Feb;92(2):680-3 [14766266.001]
  • [Cites] Eur J Surg Oncol. 2004 Nov;30(9):972-5 [15498643.001]
  • [Cites] Lancet. 1986 Nov 1;2(8514):996-9 [2430152.001]
  • [Cites] Arch Surg. 1994 Apr;129(4):390-5; discussion 395-6 [8154965.001]
  • [Cites] Ann Surg Oncol. 1998 Jul-Aug;5(5):399-406 [9718168.001]
  • [Cites] Ann Surg. 1998 Sep;228(3):355-65 [9742918.001]
  • [Cites] J Urol. 1999 Apr;161(4):1057-66 [10081838.001]
  • [Cites] CA Cancer J Clin. 1999 Jan-Feb;49(1):33-64, 1 [10200776.001]
  • [Cites] Gynecol Oncol. 1999 Oct;75(1):99-102 [10502433.001]
  • [Cites] Surg Clin North Am. 1950 Oct;30(5):1511-21 [14782163.001]
  • [Cites] Dis Colon Rectum. 2004 Dec;47(12):2047-53; discussion 2053-4 [15657653.001]
  • [Cites] Gynecol Oncol. 2005 May;97(2):524-8 [15863155.001]
  • [Cites] Int J Gynecol Cancer. 2005 May-Jun;15(3):475-82 [15882172.001]
  • [Cites] Dis Colon Rectum. 2005 May;48(5):918-28 [15785886.001]
  • [Cites] Int J Gynecol Cancer. 2005 Jul-Aug;15(4):624-9 [16014116.001]
  • [Cites] Gynecol Oncol. 2005 Oct;99(1):153-9 [16054678.001]
  • [Cites] Dis Colon Rectum. 2006 Sep;49(9):1257-65 [16912909.001]
  • [Cites] Eur J Surg Oncol. 2007 May;33(4):452-8 [17071043.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 2007 Oct;134(2):243-8 [16950559.001]
  • [Cites] Cancer. 1948 Jul;1(2):177-83 [18875031.001]
  • [Cites] Dis Colon Rectum. 1999 Nov;42(11):1438-48 [10566532.001]
  • [Cites] J Am Coll Surg. 2000 Jan;190(1):78-83 [10625236.001]
  • [Cites] World J Surg. 2001 Dec;25(12):1546-9 [11775189.001]
  • [Cites] Dis Colon Rectum. 2002 Aug;45(8):1078-84 [12195193.001]
  • [Cites] Dis Colon Rectum. 2003 Dec;46(12):1619-25 [14668586.001]
  • (PMID = 19421811.001).
  • [ISSN] 1432-2323
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2691931
  •  go-up   go-down


9. Liao X, Xin X, Lü X: Primary Ewing's sarcoma-primitive neuroectodermal tumor of the vagina. Gynecol Oncol; 2004 Feb;92(2):684-8
MedlinePlus Health Information. consumer health - Vaginal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary Ewing's sarcoma-primitive neuroectodermal tumor of the vagina.
  • BACKGROUND: Only three cases of Ewing's sarcoma-primitive neuroectodermal tumor (ES-PNET) occurring in the vagina have been previously reported.
  • CASE: A 30-year-old Chinese woman presented with a vaginal mass measuring 5 cm in greatest dimension.
  • The patient underwent wide local excision of the tumor and subsequent total abdominal hysterectomy with postoperative chemotherapy and radiotherapy.
  • CONCLUSION: This is a rare case of ES-PNET occurring in the vagina and the first showing many distinctive Homer-Wright rosettes.
  • A review of literature indicates that vaginal or vulvar ES-PNET affects younger women, and it may have a relatively favorable outcome.
  • [MeSH-major] Neuroectodermal Tumors, Primitive, Peripheral / pathology. Sarcoma, Ewing / pathology. Vaginal Neoplasms / pathology
  • [MeSH-minor] Adult. Combined Modality Therapy. Female. Humans

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14766267.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Gaona-Luviano P, Unda-Franco E, González-Jara L, Romero P, Medina-Franco H: Primitive neuroectodermal tumor of the vagina. Gynecol Oncol; 2003 Nov;91(2):456-8
MedlinePlus Health Information. consumer health - Vaginal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primitive neuroectodermal tumor of the vagina.
  • OBJECTIVES: Primitive neuroectodermal tumor is grouped together with Ewing sarcoma of the bone, but its presentation includes a wider age range and more central locations than its osseous counterpart.
  • Presentation in vagina is exceedingly rare.
  • CASE: A 34-year-old woman with personal history of kidney transplant presented with a painless vaginal mass.
  • Chemotherapy was given, followed by external beam and vaginal intracavitary brachytherapy.
  • CONCLUSIONS: This is the second case of primitive neuroectodermal tumor located in the vagina reported in the literature.
  • [MeSH-major] Neuroectodermal Tumors, Primitive / pathology. Neuroectodermal Tumors, Primitive / therapy. Vaginal Neoplasms / pathology. Vaginal Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14599885.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Bernal KL, Fahmy L, Remmenga S, Bridge J, Baker J: Embryonal rhabdomyosarcoma (sarcoma botryoides) of the cervix presenting as a cervical polyp treated with fertility-sparing surgery and adjuvant chemotherapy. Gynecol Oncol; 2004 Oct;95(1):243-6
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Embryonal rhabdomyosarcoma (sarcoma botryoides) of the cervix presenting as a cervical polyp treated with fertility-sparing surgery and adjuvant chemotherapy.
  • BACKGROUND: Embryonal rhabdomyosarcoma (sarcoma botryoides) of the female genital tract is rare in the cervix.
  • It tends to occur in children and young women, and appears to have a better prognosis than sarcoma botryoides of the vagina and uterus.
  • CASE: We report a case of embryonal rhabdomyosarcoma (sarcoma botryoides) presenting as a cervical polyp in a 19-year-old female.
  • The patient was successfully treated with fertility-sparing surgery and adjuvant chemotherapy.
  • Therapy has recently inclined towards conservative treatment.
  • [MeSH-major] Polyps / diagnosis. Polyps / therapy. Rhabdomyosarcoma, Embryonal / diagnosis. Rhabdomyosarcoma, Embryonal / therapy. Uterine Cervical Neoplasms / drug therapy. Uterine Cervical Neoplasms / therapy
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Diagnosis, Differential. Female. Fertility. Humans


12. Solomon LA, Zurawin RK, Edwards CL: Vaginoscopic resection for rhabdomyosarcoma of the vagina: a case report and review of the literature. J Pediatr Adolesc Gynecol; 2003 Jun;16(3):139-42
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vaginoscopic resection for rhabdomyosarcoma of the vagina: a case report and review of the literature.
  • Rhabdomyosarcoma is the most common soft-tissue sarcoma found in children.
  • A polypoid form of the embryonal type of rhabdomyosarcoma, sarcoma botyroides, is often found in girls under age 5.
  • These tumors are usually localized to the anterior vaginal wall.
  • Their superficial location and clinical symptoms lead to early diagnosis, and these tumors are therefore considered to be the easiest to treat and most likely to be cured.
  • In the past 30 years we have seen a shift in treatment from radical surgery to conservative surgery with chemotherapy and radiation, with improved survival and preservation of normal anatomy and improved postoperative body imagery.
  • Conservative excision in the past has been performed by sharp curettage of the anterior vaginal wall.
  • We present a case of a 2-yr-old child with a RMS of the vagina for which we utilized vaginoscopy not only to determine the extent of the tumor but also for precise resection using a bipolar electrode with normal saline as the distension medium.
  • [MeSH-major] Rhabdomyosarcoma / diagnosis. Vaginal Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Vaginal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12804937.001).
  • [ISSN] 1083-3188
  • [Journal-full-title] Journal of pediatric and adolescent gynecology
  • [ISO-abbreviation] J Pediatr Adolesc Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 10
  •  go-up   go-down


13. Ong LY, Hwang WS, Wong A, Chan MY, Chui CH: Perivascular epithelioid cell tumour of the vagina in an 8 year old girl. J Pediatr Surg; 2007 Mar;42(3):564-6
MedlinePlus Health Information. consumer health - Vaginal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Perivascular epithelioid cell tumour of the vagina in an 8 year old girl.
  • We present the first reported case of PEComa of the vagina diagnosed in an 8-year-old girl.
  • This was initially diagnosed on biopsy as an embryonal rhabdomyosarcoma, and the patient underwent 3 cycles of chemotherapy according to the Mesenchymal Malignant Tumour 1989 protocol.
  • Six months after surgery, she remains free of tumor and is on follow-up with regular local examinations under anesthesia and computed tomography scans.
  • Our case highlights the importance of an accurate initial diagnosis, and we stress the importance of regular surveillance over a significant period.
  • [MeSH-major] Epithelioid Cells / pathology. Sarcoma / therapy. Vaginal Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17336201.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Stevens M, Rey A, Bouvet N, Ellershaw C, Sanchez de Toledo J, Oberlin O: SIOP MMT 95: Intensified (6 drug) versus standard (IVA) chemotherapy for high risk non metastatic rhabdomyosarcoma (RMS). J Clin Oncol; 2004 Jul 15;22(14_suppl):8515

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] SIOP MMT 95: Intensified (6 drug) versus standard (IVA) chemotherapy for high risk non metastatic rhabdomyosarcoma (RMS).
  • Principal study objectives were: low and standard risk patients, to maintain excellent survival with limited chemotherapy and very selective use of local therapy.
  • ; high risk patients, to explore survival advantage for an intensified chemotherapy strategy in a randomised trial.
  • METHODS: Eligibility for randomisation included age ≥ 6 months ≤18 years, no distant metastases, diagnosis within previous 8 weeks without prior treatment except surgery, pathology available for central review, written consent according to institutional requirement.
  • From July 1995 to July 2003, 456 high risk patients (incompletely resected embryonal RMS, undifferentiated sarcoma and soft tissue PNET at all sites except paratesticular, vagina and uterus, and all alveolar RMS) were randomised to receive IVA (ifosfamide, vincristine, actinomycin D) or a 6 drug combination (IVA + carboplatin, epirubicin, etoposide) both delivered over 27 weeks.
  • Cumulative dose / m<sup>2</sup> = ifosfamide 54g (both arms), epirubicin 450 mg, etoposide 1350 mg (6 drug).
  • Delivery of radiotherapy was determined according to site and / or response to chemotherapy ± surgery.
  • Non randomised exceptions were: orbital tumours (allocated IVA); SIOP stage III (node positive) and young (age < 3yr) parameningeal tumours (allocated 6 drugs).
  • RESULTS: Data given only for randomised patients [Figure: see text] Toxicity was significantly greater (infection, myelosuppression, mucositis) for the 6 drug arm.
  • CONCLUSIONS: Intensification of chemotherapy provides no overall advantage for non metastatic RMS / other chemosensitive STS, and adds toxicity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28013776.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Bolaman Z, Kadikoylu G, Kafkas S, Kacar F: Granulocytic sarcoma of the ovotestis: an association of myelodysplastic syndrome and hermaphroditism. Leuk Lymphoma; 2004 Jun;45(6):1285-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granulocytic sarcoma of the ovotestis: an association of myelodysplastic syndrome and hermaphroditism.
  • EMD or granulocytic sarcoma of ovary is rare disease.
  • Her labia majora were separate and vagina hypoplastic.
  • An inguinal mass (diameter 9.5 x 7.6) cm was detected on computed tomography.
  • The histopathological diagnosis of this was obtained from laporascopy was composed of ovotestis and there was marked blastic infiltration in this ovotestis which had myeloid markers on flow cytometry.
  • No response was achieved with combination chemotherapy and the patient died from progressive leukemia.
  • [MeSH-major] Disorders of Sex Development / complications. Myelodysplastic Syndromes / complications. Ovarian Neoplasms / pathology. Sarcoma, Myeloid / pathology. Testicular Neoplasms / pathology


16. Petković M, Zamolo G, Muhvić D, Coklo M, Stifter S, Antulov R: The first report of extraosseous Ewing's sarcoma in the rectovaginal septum. Tumori; 2002 Jul-Aug;88(4):345-6
MedlinePlus Health Information. consumer health - Vaginal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The first report of extraosseous Ewing's sarcoma in the rectovaginal septum.
  • AIMS AND BACKGROUND: To report an extremely rare case of Ewing's sarcoma located in the rectovaginal septum.
  • Ewing's sarcoma is a highly malignant neoplasm of bone, which usually occurs during childhood.
  • Common extraosseous localizations of Ewing's sarcoma include the trunk, extremities, uterus, cervix and vagina.
  • The mass had a size of 9 x 6 cm, a soft tissue consistency, was partially movable and the patient felt the pain during palpation.
  • Computed tomography (CT) showed an inhomogeneous expansive mass in the rectovaginal septum measuring 8.7 x 6.1 cm, without any signs of rectum or bladder invasion.
  • Immunohistology with the monoclonal antibody CD99 (MIC-2 gene product, Ewing's sarcoma marker, clone 12E7, DAKO A/S, Glostrup, Denmark) revealed an extraosseous Ewing's sarcoma.
  • The patient was treated with chemotherapy followed by whole-pelvis external beam radiation and intracavitary brachytherapy.
  • RESULTS: A residual mass measuring 3.5 x 2.5 cm was visible on a control CT scan 18 months after treatment; however, the patient was feeling well and refused surgery to remove the residual mass.
  • CONCLUSIONS: To our knowledge this is the first reported case of extraosseous Ewing's sarcoma in the rectovaginal septum.
  • [MeSH-major] Rectal Neoplasms / therapy. Sarcoma, Ewing / therapy. Vaginal Neoplasms / therapy

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12400989.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Sajdak S, Moszynski R, Opala T: Bleeding from endometrial and vaginal malignant tumors treated with activated recombinant factor VII. Eur J Gynaecol Oncol; 2002;23(4):325-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bleeding from endometrial and vaginal malignant tumors treated with activated recombinant factor VII.
  • The authors report two cases of successful employment of human recombinant activated factor VII in gynecological oncological patients (endometrial cancer and vaginal sarcoma) without pre-existing coagulopathy.
  • They conclude that recombinant factor VIIa may be an important and effective drug in severe bleeding in gynecological oncology.
  • [MeSH-major] Factor VII Deficiency / drug therapy. Factor VIIa / administration & dosage. Hemostatics / administration & dosage. Uterine Hemorrhage / drug therapy. Uterine Hemorrhage / etiology
  • [MeSH-minor] Adenocarcinoma / complications. Adenocarcinoma / radiotherapy. Administration, Intravaginal. Adult. Aged. Endometrial Neoplasms / complications. Endometrial Neoplasms / radiotherapy. Ethamsylate / administration & dosage. Female. Humans. Infusions, Intravenous. Mandibular Neoplasms / complications. Mandibular Neoplasms / secondary. Mandibular Neoplasms / therapy. Neoplasm Metastasis. Neoplasm Recurrence, Local. Recombinant Proteins. Sarcoma / complications. Sarcoma / secondary. Sarcoma / therapy. Tranexamic Acid / administration & dosage. Vaginal Neoplasms / complications. Vaginal Neoplasms / pathology. Vaginal Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Vaginal Bleeding.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12214734.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Hemostatics; 0 / Recombinant Proteins; 24YL531VOH / Ethamsylate; 6T84R30KC1 / Tranexamic Acid; EC 3.4.21.21 / Factor VIIa
  •  go-up   go-down


18. Gruessner SE, Omwandho CO, Dreyer T, Blütters-Sawatzki R, Reiter A, Tinneberg HR, Bohle RM: Management of stage I cervical sarcoma botryoides in childhood and adolescence. Eur J Pediatr; 2004 Aug;163(8):452-6
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of stage I cervical sarcoma botryoides in childhood and adolescence.
  • Rhabdomyosarcomas are the most common soft tissue sarcomas in childhood.
  • The botryoid variant arises in infancy from the vagina or urinary bladder and extremely rarely from the uterine cervix.
  • Treatment regimes range from local excision of the tumour to radical hysterectomy with adjuvant multidrug therapy and/or radiotherapy.
  • In cases of minimal cervical invasion, the less invasive local excision in combination with adjuvant chemotherapy has resulted in excellent survival rates with complete functional preservation of the bladder, rectum, vagina, and ovaries.
  • We present here a 30-year literature review and a case report of a cervical sarcoma botryoides in a 5-year-old girl.
  • CONCLUSION: based on the literature review and our own observation, we recommend minor surgical approaches in combination with chemotherapy as the treatment of choice for early stage I cervical rhabdomyosarcoma.
  • [MeSH-major] Rhabdomyosarcoma, Embryonal / pathology. Rhabdomyosarcoma, Embryonal / therapy. Uterine Cervical Neoplasms / pathology. Uterine Cervical Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols. Chemotherapy, Adjuvant. Child, Preschool. Dactinomycin / therapeutic use. Female. Humans. Ifosfamide / therapeutic use. Neoplasm Staging. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Sarcoma botryoides.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 Springer-Verlag
  • [Cites] Eur J Cancer. 2001 Apr;37(6):767-74 [11311652.001]
  • [Cites] Surg Clin North Am. 2000 Apr;80(2):747-60, xii [10836015.001]
  • [Cites] Obstet Gynecol. 1975 Feb;45(2):175-80 [1090863.001]
  • [Cites] Cancer. 1987 Oct 1;60(7):1552-60 [3621128.001]
  • [Cites] AJR Am J Roentgenol. 2001 Jun;176(6):1563-9 [11373233.001]
  • [Cites] Best Pract Res Clin Obstet Gynaecol. 2003 Feb;17(1):149-68 [12758232.001]
  • [Cites] Prostate Cancer Prostatic Dis. 2003;6(2):112-20 [12806368.001]
  • [Cites] Cancer. 1975 Mar;35(3):677-86 [1111936.001]
  • [Cites] Eur J Gynaecol Oncol. 2000;21(5):499-500 [11198042.001]
  • [Cites] J Pediatr Surg. 1985 Dec;20(6):718-24 [3910785.001]
  • [Cites] Cancer. 1988 Jan 15;61(2):209-20 [3275486.001]
  • [Cites] Cancer. 2003 May 15;97(10):2597-604 [12733159.001]
  • [Cites] Eur J Gynaecol Oncol. 1996;17(5):335-7 [8933824.001]
  • [Cites] Gynecol Oncol. 1997 Oct;67(1):102-6 [9345364.001]
  • [Cites] J Surg Oncol. 2001 May;77(1):65-71 [11344486.001]
  • [Cites] Med Pediatr Oncol. 2003 Jul;41(1):1-6 [12764734.001]
  • [Cites] J Clin Oncol. 2000 Jun;18(12):2427-34 [10856103.001]
  • [Cites] J Pediatr Hematol Oncol. 2003 Jun;25(6):448-52 [12794522.001]
  • [Cites] Eur J Cancer. 1998 Jun;34(7):1050-62 [9849454.001]
  • [Cites] Ann N Y Acad Sci. 1967 May 10;142(3):694-708 [5231254.001]
  • [Cites] J Clin Oncol. 2001 Jun 15;19(12):3091-102 [11408506.001]
  • [Cites] Am J Surg. 2002 Dec;184(6):484-91 [12488143.001]
  • [Cites] Med Pediatr Oncol. 2001 Apr;36(4):481-8 [11260572.001]
  • [Cites] Gynecol Oncol. 1990 Jan;36(1):119-24 [2403958.001]
  • [Cites] J Clin Oncol. 1995 Mar;13(3):610-30 [7884423.001]
  • [Cites] J Pediatr Surg. 1999 May;34(5):731-4; discussion 734-5 [10359173.001]
  • [Cites] Obstet Gynecol. 1985 Aug;66(2):262-6 [3839576.001]
  • [Cites] Arch Dis Child. 2003 Apr;88(4):354-7 [12651771.001]
  • [Cites] Cancer. 1973 Dec;32(6):1310-6 [4202189.001]
  • [Cites] J Clin Oncol. 1999 Jul;17(7):2117-22 [10561266.001]
  • (PMID = 15173941.001).
  • [ISSN] 0340-6199
  • [Journal-full-title] European journal of pediatrics
  • [ISO-abbreviation] Eur. J. Pediatr.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 1CC1JFE158 / Dactinomycin; 5J49Q6B70F / Vincristine; UM20QQM95Y / Ifosfamide
  • [Number-of-references] 32
  •  go-up   go-down


19. Atlante M, Dionisi B, Cioni M, Di Ruzza D, Sedati P, Mariani L: Sarcoma botryoides of the uterine cervix in a young woman: a case report. Eur J Gynaecol Oncol; 2000;21(5):504-6
MedlinePlus Health Information. consumer health - Cervical Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sarcoma botryoides of the uterine cervix in a young woman: a case report.
  • Among the rhabdomyosarcomas, which represent an uncommon neoplasm of mesoderm origin comprising about 1% of all female genital malignancies, sarcoma botryoides (SB) is an embrional variant usually found in the vagina of infants and young children under 16 years of age.
  • The authors report a case of embryonal rhabdomyosarcoma of the uterine cervix which occurred in a young woman treated by radical surgery, followed by adjuvant chemotherapy and radiotherapy.
  • [MeSH-major] Rhabdomyosarcoma, Embryonal / therapy. Uterine Cervical Neoplasms / therapy
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Female. Humans. Radiotherapy, Adjuvant

  • Genetic Alliance. consumer health - Sarcoma botryoides.
  • Genetic Alliance. consumer health - Uterine sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11198044.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


20. Miyamoto T, Shiozawa T, Nakamura T, Konishi I: Sarcoma botryoides of the uterine cervix in a 46-year-old woman: case report and literature review. Int J Gynecol Pathol; 2004 Jan;23(1):78-82
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sarcoma botryoides of the uterine cervix in a 46-year-old woman: case report and literature review.
  • Sarcoma botryoides, which usually occurs in the vagina in childhood, is rare in the female reproductive tract of adult women, especially those over the age of 40.
  • We present a case of sarcoma botryoides of the uterine cervix that was an incidental finding in a 46-year-old woman.
  • Postoperative chemotherapy (vincristine and actinomycin D) was given according to the Intergroup Rhabdomyosarcoma Study protocol, and the patient was alive without recurrence 45 months postoperatively.
  • This is the only the fourth case reported in detail of a sarcoma botryoides of the uterine cervix in a patient over the age of 40.
  • [MeSH-minor] Age of Onset. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Middle Aged. MyoD Protein / metabolism. Myogenin / metabolism. Neoplasm Recurrence, Local. Polyps / pathology

  • Genetic Alliance. consumer health - Sarcoma botryoides.
  • Genetic Alliance. consumer health - Uterine sarcoma.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14668557.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MYOG protein, human; 0 / MyoD Protein; 0 / MyoD1 myogenic differentiation protein; 0 / Myogenin
  •  go-up   go-down


21. Goker BO, Bese T, Ilvan S, Yilmaz E, Demirkiran F: A case with multiple gynecological malignancies. Int J Gynecol Cancer; 2005 Mar-Apr;15(2):372-6
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A patient with cervical non-Hodgkin lymphoma was treated with chemotherapy.
  • Fourteen months after the diagnosis of the lymphoma, an endometrial adenocarcinoma was detected as a secondary malignant tumor.
  • Approximately 7 years after the diagnosis of endometrial cancer, vaginal invasive squamous cell carcinoma was diagnosed as the third primary malignancy, and a second-line palliative radiotherapy was applied.
  • Seven months after the last radiotherapy, postradiational sarcoma in the vagina was diagnosed.
  • Congenital and acquired immune system disorders, viral oncogenes, and various human leukocyte antigen (HLA) types were investigated.
  • [MeSH-major] Adenocarcinoma / pathology. Endometrial Neoplasms / pathology. Lymphoma, Non-Hodgkin / drug therapy. Neoplasms, Multiple Primary / pathology. Sarcoma / pathology. Uterine Cervical Neoplasms / drug therapy. Vaginal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • MedlinePlus Health Information. consumer health - Vaginal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15823128.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Cecchetto G, Carretto E, Bisogno G, Dall'Igna P, Ferrari A, Scarzello G, Donfrancesco A, Alaggio R, Indolfi P, Carli M: Complete second look operation and radiotherapy in locally advanced non-alveolar rhabdomyosarcoma in children: A report from the AIEOP soft tissue sarcoma committee. Pediatr Blood Cancer; 2008 Nov;51(5):593-7
Genetic Alliance. consumer health - Soft tissue sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete second look operation and radiotherapy in locally advanced non-alveolar rhabdomyosarcoma in children: A report from the AIEOP soft tissue sarcoma committee.
  • PROCEDURE: We analyzed data from 39 patients (age: 0.5-194 months, median 52) who were enrolled between 1988 and 2005 in 2 consecutive Italian Studies, RMS 88 and RMS 96.
  • All achieved a complete resection of the residual tumor after neoadjuvant chemotherapy; 27 did not receive any other local treatment: pelvic 8, extremities 6, head-neck-non-parameningeal 5, orbit 1, genito-urinary-bladder-prostate 3, trunk 2, abdomen 1, vagina 1; 12 were given RT (32-45 Gy), 5 before and 7 after the operation: genito-urinary-bladder-prostate 3, pelvic 3, abdominal 1, extremities 1, head-neck-parameningeal 1, head-neck-non-parameningeal 1, vagina 1, orbit 1.
  • All received postoperative chemotherapy.
  • Without RT: 16/27 maintained the first complete remission, however 1/16 died due to a second tumor; 8 suffered from local relapse (4 pelvic, 1 orbit, 1 vagina, 1 head-neck-non-parameningeal, 1 abdomen) and 3 of them died, 3 showed a metastatic recurrence (2 extremities, 1 pelvic) and 1 died.
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Child. Child, Preschool. Clinical Trials as Topic. Combined Modality Therapy. Female. Humans. Infant. Kaplan-Meier Estimate. Male. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / therapy. Radiotherapy, Adjuvant. Sarcoma

  • Genetic Alliance. consumer health - Rhabdomyosarcoma alveolar.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18668515.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


23. Murphy KT, Rotmensch J, Yamada SD, Mundt AJ: Outcome and patterns of failure in pathologic stages I-IV clear-cell carcinoma of the endometrium: implications for adjuvant radiation therapy. Int J Radiat Oncol Biol Phys; 2003 Apr 1;55(5):1272-6
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome and patterns of failure in pathologic stages I-IV clear-cell carcinoma of the endometrium: implications for adjuvant radiation therapy.
  • PURPOSE: To evaluate the outcome and patterns of failure in women with uterine clear-cell carcinoma and discuss implications for adjuvant radiation therapy (RT).
  • Thirty-eight women (5.5%) had clear-cell tumors (18 clear-cell only, 8 clear-cell + adenocarcinoma, and 12 clear-cell + other unfavorable histologies [10 papillary serous, 1 uterine sarcoma, 1 both]).
  • Adjuvant therapies included the following: 5 none, 22 RT (13 pelvic RT, 2 vaginal brachytherapy, 7 both), 11 chemotherapy (8 alone, 3 after pelvic RT), and 3 hormones.
  • Eight failed in the pelvis (5 vagina, 3 lateral pelvis).
  • Only 1 (2%) patient developed an isolated abdominal failure (This patient had a mixed clear-cell/papillary serous tumor).
  • Future protocols should focus instead on combinations of locoregional RT and chemotherapy to reduce the risk of local and systemic recurrence.
  • [MeSH-minor] Abdominal Neoplasms / secondary. Adenocarcinoma / drug therapy. Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma / radiotherapy. Adenocarcinoma / secondary. Adenocarcinoma / surgery. Adult. Aged. Aged, 80 and over. Bone Neoplasms / secondary. Brachytherapy. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Combined Modality Therapy. Cystadenocarcinoma / pathology. Disease-Free Survival. Female. Follow-Up Studies. Humans. Hysterectomy. Life Tables. Lung Neoplasms / secondary. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Neoplasms, Multiple Primary / drug therapy. Neoplasms, Multiple Primary / mortality. Neoplasms, Multiple Primary / pathology. Neoplasms, Multiple Primary / radiotherapy. Neoplasms, Multiple Primary / surgery. Pelvic Neoplasms / secondary. Prognosis. Sarcoma / pathology. Treatment Failure. Treatment Outcome. Uterine Neoplasms / pathology. Vaginal Neoplasms / secondary

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12654437.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin
  • [Number-of-references] 30
  •  go-up   go-down


24. Perez-Brayfield MR, Smith EA, Gatti J, Bergsagel J, Namnoun J: Vaginal reconstruction using a vertical rectus abdominis myocutaneous flap in a child: a case report. J Pediatr Surg; 2001 Jul;36(7):1070-2
MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vaginal reconstruction using a vertical rectus abdominis myocutaneous flap in a child: a case report.
  • Rhabdomyosarcoma is the most common soft tissue sarcoma in infants and children younger than 15 years old.
  • Multimodal treatment using chemotherapy, radiation, and surgery have increased survival.
  • Because of the potential for long-term survival, the importance of organ preservation and vaginal and pelvic reconstruction has been recognized.
  • The authors report a case in which special circumstances led to vaginal reconstruction concomitantly with exenteration surgery.
  • [MeSH-major] Reconstructive Surgical Procedures / methods. Rhabdomyosarcoma, Embryonal / surgery. Surgical Flaps. Urogenital Neoplasms / surgery. Vagina / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 by W.B. Saunders Company.
  • (PMID = 11431782.001).
  • [ISSN] 0022-3468
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Kortmann B, Reimer T, Gerber B, Klautke G, Fietkau R: Concurrent radiochemotherapy of locally recurrent or advanced sarcomas of the uterus. Strahlenther Onkol; 2006 Jun;182(6):318-24
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Until now, no data on the treatment of recurrent or advanced uterine sarcomas using concurrent radiochemotherapy (RCT) has been available.
  • A total radiation dose of 45 Gy was applied in single doses of 1.8 Gy using an external-beam technique; in addition, three to four intracavitary doses of 5 Gy were applied.
  • Concurrent chemotherapy was generally administered as follows: 1.2 g/m(2) ifosfamide on days 1-5 and 29-33 in combination with 50 or 40 mg/m(2) adriamycin on days 2 and 30.
  • 3/7 patients received further cycles of chemotherapy.
  • RESULTS: All recurrences (before RCT) were localized either in the vagina or in or directly proximal to the vaginal stump.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Neoplasm Recurrence, Local / prevention & control. Radiotherapy, Conformal / methods. Sarcoma / therapy. Uterine Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Dose-Response Relationship, Drug. Dose-Response Relationship, Radiation. Doxorubicin / administration & dosage. Female. Humans. Ifosfamide / administration & dosage. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16703286.001).
  • [ISSN] 1439-099X
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 80168379AG / Doxorubicin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


26. Shamseddine A, Taher A, Abou-Mourad Y, Seoud M, Khalil A: Cure of metastatic uterine carcinosarcoma to lungs: a case report. Int J Gynecol Cancer; 2003 Jan-Feb;13(1):88-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Most patients with advanced or recurrent uterine sarcoma experience disease progression and ultimately die.
  • We present a case of uterine sarcoma with lung metastasis treated with systemic chemotherapy and with no evidence of disease for more than 5 years.
  • Ten months later, the tumor recurred in the apex of the vagina and was treated with brachytherapy.
  • After four cycles of systemic chemotherapy with cisplatin and ifosfamide, the pulmonary nodules completely disappeared.
  • Currently she is still in complete remission after more than 5 years, but unfortunately she has developed myelodysplastic syndrome.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinosarcoma / drug therapy. Carcinosarcoma / secondary. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Uterine Neoplasms / pathology
  • [MeSH-minor] Aged. Cisplatin / administration & dosage. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Ifosfamide / administration & dosage

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12631227.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


27. Mangino M, Schena FP: [Skin cancer in renal transplant recipients]. G Ital Nefrol; 2010 Sep-Oct;27 Suppl 50:S75-80
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Skin cancer in renal transplant recipients].
  • Kidney transplant is the best treatment option for renal failure.
  • It is known that the incidence of cancer increases with the duration of post-transplant follow-up.
  • Twenty years after transplantation, approximately 70% of patients on continuous immunosuppressive therapy present one or more tumor types.
  • Examples are herpes virus 8 (HHV8), implicated in Kaposi's sarcoma (KS), human papillomavirus (HPV), involved in squamous cell cancer of the skin, vulva, vagina and cervix, and Epstein-Barr virus (EBV), responsible for post-transplant lymphoproliferative disorder (PTLD).
  • The type of drug used for the induction and maintenance of immunosuppression and the duration of treatment influence both the incidence and the type of cancer.
  • It is estimated that sarcomas occur 40 to 250 times more frequently in transplant recipients and are the leading cause of death from skin cancer after transplantation.
  • The reduction or suspension of immunosuppressive therapy is the first step in the treatment of post-transplant KS.
  • The second approach is chemotherapy.
  • In conclusion, new strategies must be developed to reduce cancer mortality in transplant recipients while ensuring adequate immunosuppression to preserve the transplanted organ.
  • [MeSH-minor] Humans. Sarcoma, Kaposi / chemically induced

  • Genetic Alliance. consumer health - Kidney cancer.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20922700.001).
  • [ISSN] 0393-5590
  • [Journal-full-title] Giornale italiano di nefrologia : organo ufficiale della Società italiana di nefrologia
  • [ISO-abbreviation] G Ital Nefrol
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  •  go-up   go-down


28. Maharaj NR, Nimako D, Hadley GP: Multimodal therapy for the initial management of genital embryonal rhabdomyosarcoma in childhood. Int J Gynecol Cancer; 2008 Jan-Feb;18(1):190-2
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multimodal therapy for the initial management of genital embryonal rhabdomyosarcoma in childhood.
  • Rhabdomyosarcoma is the most common soft tissue sarcoma found in children.
  • A polypoid form of the embryonal type of rhabdomyosarcoma, namely, sarcoma botryoides, is often found in girls younger than 5 years, and typically presents as a polypoid mass protruding from the vagina.
  • Over the years, there has been a shift in the treatment of this condition from radical surgery to a multimodal approach involving conservative surgery with chemotherapy and radiotherapy.
  • [MeSH-major] Pelvic Neoplasms / therapy. Rhabdomyosarcoma, Embryonal / therapy
  • [MeSH-minor] Child, Preschool. Combined Modality Therapy. Female. Humans

  • Genetic Alliance. consumer health - Rhabdomyosarcoma embryonal.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17511807.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


29. Ojwang SB, Rana F, Sayed S, Aruasa WK: Embryonal rhabdomyosarcoma with uterine inversion: case report. East Afr Med J; 2006 Mar;83(3):110-3
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • She had been referred with a one year history of continuous vaginal bleeding and vaginal swelling.
  • Histology had shown sarcoma botyroides and had received five courses of chemotherapy at the referring hospital.
  • [MeSH-minor] Adolescent. Female. Humans. Hysterectomy. Radiotherapy, Adjuvant. Uterine Hemorrhage. Vagina / physiopathology

  • Genetic Alliance. consumer health - Rhabdomyosarcoma embryonal.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16771108.001).
  • [ISSN] 0012-835X
  • [Journal-full-title] East African medical journal
  • [ISO-abbreviation] East Afr Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Kenya
  •  go-up   go-down


30. Song JS, Kim IK, Kim YM, Khang SK, Kim KR, Lee Y: Extrarenal teratoid Wilms' tumor: two cases in unusual locations, one associated with elevated serum AFP. Pathol Int; 2010 Jan;60(1):35-41
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Teratoid Wilms' tumor is an unusual morphological entity characterized by a classic triphasic malignancy with predominantly heterologous tissue.
  • The authors describe two cases of teratoid Wilms' tumor with an extrarenal site: one in a 13-year-old girl with vaginal spotting (patient 1) and another in a 1-day-old girl with a sacrococcygeal mass (patient 2).
  • The tumors were located in the vagina and coccyx, respectively.
  • Under the initial clinical diagnosis of sarcoma botryoides in patient 1 and teratoma in patient 2, the masses were removed.
  • Microscopically, both tumors were composed of typical triphasic Wilms' tumor tissue with primitive cartilage and skeletal muscle, and squamous and columnar mucinous epithelia.
  • The patients were given chemotherapy and have now remained disease free for 7 years 1 month, and 2 years 5 months after surgery, respectively.
  • Familiarity with this rare variant of Wilms' tumor might be important in arriving at a correct diagnosis.
  • [MeSH-major] Coccyx / pathology. Spinal Neoplasms / pathology. Vaginal Neoplasms / pathology. Wilms Tumor / pathology. alpha-Fetoproteins / analysis
  • [MeSH-minor] Adolescent. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / therapeutic use. Dactinomycin / therapeutic use. Disease-Free Survival. Female. Humans. Infant, Newborn. Pregnancy. Prenatal Diagnosis. Teratoma / drug therapy. Teratoma / pathology. Teratoma / surgery. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Wilms' tumor.
  • MedlinePlus Health Information. consumer health - Vaginal Cancer.
  • MedlinePlus Health Information. consumer health - Wilms Tumor.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20055950.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / alpha-Fetoproteins; 1CC1JFE158 / Dactinomycin; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


31. Polish Paediatric Solid Tumours Study Group, Bień E, Stachowicz-Stencel T, Kazanowska B, Balcerska A, Balwierz W, Chybicka A, Dłuzniewska A, Drozyńska E, Kurylak A, Matysiaks M, Krawczuk-Rybak M, Rychłowska M, Solarz E, Sopyło B, Stencels D, Wachowiaks J, Wieczorek M, Woźniak W, Wysocki M: [Genitourinary soft tissue sarcomas located outside bladder and prostate in children treated according to the CWS-96 protocol--report from the Polish Paediatric Solid Tumours Study Group]. Med Wieku Rozwoj; 2005 Jul-Sep;9(3 Pt 2):507-15
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Genitourinary soft tissue sarcomas located outside bladder and prostate in children treated according to the CWS-96 protocol--report from the Polish Paediatric Solid Tumours Study Group].
  • AIM: Analysis of therapy efficacy in non-bladder/prostate genitourinary sarcomas in children treated from I'1997 to VI'2003 with CWS-96 protocol in Poland.
  • RESULTS: Primary site: testes - 9 patients, paratesticular region - 6, uterus - 2, vagina and ovary-1 of each.
  • Primary tumour exceeded 5cm and/or invaded surrounding tissues in 7 patients (37%).
  • Six of 7 patients with macroscopic tumour residues responded to chemotherapy (CR-4, GR-2).
  • Radiotherapy (23,5-54 Gy) was given to 8 patients.
  • 3 children developed local relapse, 3 patients died (16%): 2 due to neoplasm progression, 1 of neutropenia-related sepsis.
  • 2) chemotherapy and radiotherapy were accompanied by severe but transient myelosupression in the HR group.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Rhabdomyosarcoma / diagnosis. Rhabdomyosarcoma / drug therapy. Sarcoma / diagnosis. Sarcoma / drug therapy. Urogenital Neoplasms / diagnosis. Urogenital Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Humans. Infant. Lymphatic Metastasis. Male. Neoplasm Staging. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16719163.001).
  • [Journal-full-title] Medycyna wieku rozwojowego
  • [ISO-abbreviation] Med Wieku Rozwoj
  • [Language] pol
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


32. Calleja Aguayo E, Delgado Alvira R, Elías Pollina J, Romeo Ulecia M, González Esgueda A, Esteban Ibarz JA: [Differential diagnosis of the interlabial masses in girls under 5-years-old]. Cir Pediatr; 2010 Jan;23(1):28-31
MedlinePlus Health Information. consumer health - Vulvar Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Differential diagnosis of the interlabial masses in girls under 5-years-old].
  • The masses that we can be found at interlabial in a girl are a extensive spectrum of heterogenous lesions and often there is a confusion in diagnosis, management and prognosis.
  • METHODS: We present 5 cases of interlabial masses, prolapsed urethra, two paraurethral Skene cysts, botryoid sarcoma and fibroepithelial polyp, and its clinical of debut.
  • RESULTS: A prolapsed urethra is presented in a 4-year-old black girl with vaginal bleeding from edamatous periurethral mass.
  • The botryoid sarcoma appears in a 1-year-old girl with ulcerated polypoid mass of 2 cm from vagina.
  • All cases were treated with surgery except the paraurethral cyst that drained spontaneously and the rhabdomyosarcoma was also treated with chemotherapy.
  • The surgery is indicated mainly to reject malignancy because the presentation of sarcoma and polyp could be similar.
  • The prognosis of rhabdomyosarcoma vaginal is good with surgery and chemotherapy.
  • [MeSH-major] Vulvar Diseases / diagnosis
  • [MeSH-minor] Child, Preschool. Diagnosis, Differential. Female. Humans. Infant. Infant, Newborn

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20578574.001).
  • [ISSN] 0214-1221
  • [Journal-full-title] Cirugía pediátrica : organo oficial de la Sociedad Española de Cirugía Pediátrica
  • [ISO-abbreviation] Cir Pediatr
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


33. Rigor BM Sr: Pelvic cancer pain. J Surg Oncol; 2000 Dec;75(4):280-300
MedlinePlus Health Information. consumer health - Pelvic Pain.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pelvic cancer pain.
  • Pelvic cancer causes several types of pain, i.e., visceral, neuropathic, and somatic pain.
  • In 60% of patients with malignant disease of soft tissues, nerve trunk, and sacral invasion from carcinoma of the cervix, uterus, vagina, colon, rectum, and other tissues in women, and from penile, prostate, and colorectal carcinoma and sarcoma in men, they have neuropathic pain.
  • Pain of these types is managed by different modalities depending on the age of the patient, the expected life expectancy, availability of invasive and non-invasive pain control modalities, and the resources of the patient, community, and health care agencies.
  • Patients with pelvic cancer can live with less pain due to better pain-control modalities that are available today with the help of dedicated and caring algologists.
  • [MeSH-minor] Afferent Pathways / physiology. Analgesia, Patient-Controlled. Analgesics, Opioid / therapeutic use. Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Antineoplastic Agents / therapeutic use. Chronic Disease. Combined Modality Therapy. Drug Administration Routes. Female. Home Care Services. Humans. Hypogastric Plexus / physiopathology. Male. Nerve Block. Spinal Cord / physiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 Wiley-Liss, Inc.
  • (PMID = 11135274.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Analgesics, Opioid; 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Antineoplastic Agents
  • [Number-of-references] 46
  •  go-up   go-down


34. Polin SA, Ascher SM: The effect of tamoxifen on the genital tract. Cancer Imaging; 2008;8:135-45
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tamoxifen is a selective estrogen receptor modulator (SERM) that is widely used in the treatment of patients with breast cancer and for chemoprophylaxis in high risk women.
  • Tamoxifen results in a spectrum of abnormalities involving the genital tract, the most significant being an increased incidence of endometrial cancer and uterine sarcoma.
  • [MeSH-major] Antineoplastic Agents, Hormonal / adverse effects. Breast Neoplasms / drug therapy. Female Urogenital Diseases / chemically induced. Female Urogenital Diseases / ultrasonography. Tamoxifen / adverse effects
  • [MeSH-minor] Adult. Aged. Cervix Uteri / drug effects. Cervix Uteri / ultrasonography. Chemotherapy, Adjuvant. Dose-Response Relationship, Drug. Drug Administration Schedule. Endosonography / methods. Female. Follow-Up Studies. Humans. Incidence. Magnetic Resonance Imaging / methods. Middle Aged. Ovary / drug effects. Ovary / ultrasonography. Risk Assessment. Vagina / drug effects. Vagina / ultrasonography

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Pathol. 1999 Feb;52(2):83-8 [10396232.001]
  • [Cites] Breast Cancer Res Treat. 1999 Apr;54(3):255-60 [10445424.001]
  • [Cites] Gynecol Oncol. 1999 Oct;75(1):136-41 [10502440.001]
  • [Cites] Eur J Gynaecol Oncol. 2005;26(3):257-65 [15991522.001]
  • [Cites] Obstet Gynecol. 2006 Jun;107(6):1475-8 [16738185.001]
  • [Cites] J Clin Oncol. 1999 Jul;17(7):2050-4 [10561257.001]
  • [Cites] Radiology. 2000 Jan;214(1):29-38 [10644098.001]
  • [Cites] Drug Saf. 2000 Jan;22(1):1-11 [10647972.001]
  • [Cites] Gynecol Oncol. 2000 Aug;78(2):181-6 [10926800.001]
  • [Cites] Cancer. 2000 Aug 15;89(4):800-10 [10951343.001]
  • [Cites] J Clin Oncol. 2000 Oct 15;18(20):3459-63 [11032585.001]
  • [Cites] J Clin Oncol. 2000 Oct 15;18(20):3464-70 [11032586.001]
  • [Cites] Lancet. 2000 Sep 9;356(9233):881-7 [11036892.001]
  • [Cites] Lancet. 2001 Jan 6;357(9249):65-6; author reply 67 [11197376.001]
  • [Cites] Lancet. 2001 Jan 6;357(9249):66-7 [11197379.001]
  • [Cites] Obstet Gynecol. 2001 May;97(5 Pt 2):855-66 [11336777.001]
  • [Cites] Radiology. 2001 Sep;220(3):765-73 [11526280.001]
  • [Cites] Radiographics. 2003 Jan-Feb;23(1):137-50; discussion 151-5 [12533649.001]
  • [Cites] Eur J Gynaecol Oncol. 2003;24(3-4):258-68 [12807236.001]
  • [Cites] J Ultrasound Med. 2003 Nov;22(11):1173-9 [14620887.001]
  • [Cites] Gynecol Oncol. 2004 Feb;92(2):553-8 [14766247.001]
  • [Cites] Cancer Treat Rev. 2004 May;30(3):291-301 [15059652.001]
  • [Cites] Gynecol Oncol. 2004 May;93(2):328-35 [15099941.001]
  • [Cites] Gynecol Oncol. 2004 Aug;94(2):256-66 [15297160.001]
  • [Cites] Br Med J. 1971 Jan 16;1(5741):152-4 [5539422.001]
  • [Cites] Br Med J. 1977 May 21;1(6072):1351-2 [861624.001]
  • [Cites] J Ultrasound Med. 1996 Apr;15(4):285-8 [8683662.001]
  • [Cites] Gynecol Oncol. 1996 Mar;60(3):409-11 [8774648.001]
  • [Cites] Breast Cancer Res Treat. 1996;38(2):183-99 [8861837.001]
  • [Cites] Clin Obstet Gynecol. 1996 Sep;39(3):629-40 [8862888.001]
  • [Cites] Semin Roentgenol. 1996 Oct;31(4):288-98 [8896105.001]
  • [Cites] AJR Am J Roentgenol. 1997 Mar;168(3):657-61 [9057510.001]
  • [Cites] Gynecol Oncol. 1997 Mar;64(3):386-91 [9062139.001]
  • [Cites] AJR Am J Roentgenol. 1997 Jul;169(1):145-9 [9207515.001]
  • [Cites] Gynecol Oncol. 1997 Aug;66(2):233-7 [9264568.001]
  • [Cites] N Engl J Med. 1997 Dec 18;337(25):1792-8 [9400035.001]
  • [Cites] Lancet. 1998 Jan 3;351(9095):36 [9433432.001]
  • [Cites] Lancet. 1998 Jan 17;351(9097):155-7 [9449866.001]
  • [Cites] Obstet Gynecol. 1998 Jan;91(1):40-4 [9464718.001]
  • [Cites] Int J Cancer. 1998 May 4;76(3):325-30 [9579567.001]
  • [Cites] Lancet. 1998 May 16;351(9114):1451-67 [9605801.001]
  • [Cites] J Clin Oncol. 1998 Jun;16(6):2018-24 [9626198.001]
  • [Cites] Am J Obstet Gynecol. 1998 Jun;178(6):1145-50 [9662294.001]
  • [Cites] J Natl Cancer Inst. 1998 Sep 16;90(18):1371-88 [9747868.001]
  • [Cites] Int J Gynecol Pathol. 1998 Oct;17(4):302-11 [9785130.001]
  • [Cites] N Engl J Med. 1998 Nov 26;339(22):1609-18 [9828250.001]
  • [Cites] Diagn Cytopathol. 1998 Dec;19(6):417-22 [9839130.001]
  • [Cites] Gynecol Oncol. 1999 Apr;73(1):21-6 [10094875.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1488-92 [10334535.001]
  • [Cites] AJR Am J Roentgenol. 1999 Jun;172(6):1513-20 [10350282.001]
  • [Cites] Obstet Gynecol. 1999 Jun;93(6):1004-8 [10362171.001]
  • [Cites] J Natl Cancer Inst. 1994 Apr 6;86(7):527-37 [8133536.001]
  • [Cites] Lancet. 1994 May 28;343(8909):1318-21 [7910323.001]
  • [Cites] Radiographics. 1994 May;14(3):483-92 [8066264.001]
  • [Cites] Am J Obstet Gynecol. 1994 Sep;171(3):722-8 [8092221.001]
  • [Cites] J Ultrasound Med. 1994 Feb;13(2):99-104 [7932969.001]
  • [Cites] J Clin Pathol. 1994 Sep;47(9):827-33 [7962652.001]
  • [Cites] Gynecol Oncol. 1994 Dec;55(3 Pt 1):410-4 [7835781.001]
  • [Cites] Obstet Gynecol Surv. 1994 Dec;49(12):823-9 [7885659.001]
  • [Cites] Am J Obstet Gynecol. 1995 May;172(5):1488-94 [7755059.001]
  • [Cites] Gynecol Oncol. 1995 Jul;58(1):86-91 [7789896.001]
  • [Cites] Radiographics. 1995 May;15(3):501-14; discussion 515-6 [7624559.001]
  • [Cites] J Natl Cancer Inst. 1995 Sep 20;87(18):1359-64 [7658496.001]
  • [Cites] J Ultrasound Med. 1995 Sep;14(9):685-8 [7500435.001]
  • [Cites] Oncology. 1981;38(5):281-5 [7266969.001]
  • [Cites] Acta Obstet Gynecol Scand. 1983;62(5):393-6 [6421082.001]
  • [Cites] Radiology. 1987 Feb;162(2):297-305 [3797641.001]
  • [Cites] Fertil Steril. 1989 Dec;52(6):924-9 [2531684.001]
  • [Cites] Am J Obstet Gynecol. 1990 Jul;163(1 Pt 1):119-23 [2197861.001]
  • [Cites] Am J Obstet Gynecol. 1991 Jan;164(1 Pt 1):47-52 [1986624.001]
  • [Cites] J Natl Cancer Inst. 1991 Jul 17;83(14):1013-7 [2072407.001]
  • [Cites] Radiology. 1991 Oct;181(1):95-106 [1887062.001]
  • [Cites] Gynecol Oncol. 1991 Aug;42(2):120-3 [1894169.001]
  • [Cites] Obstet Gynecol. 1992 Jan;79(1):111-6 [1727568.001]
  • [Cites] Am J Obstet Gynecol. 1992 Jan;166(1 Pt 1):167-8 [1733191.001]
  • [Cites] AJR Am J Roentgenol. 1993 Mar;160(3):533-8 [8430547.001]
  • [Cites] J Clin Oncol. 1993 Mar;11(3):485-90 [8383191.001]
  • [Cites] AJR Am J Roentgenol. 1993 Apr;160(4):809-12 [8456669.001]
  • [Cites] Obstet Gynecol. 1993 May;81(5 ( Pt 1)):660-4 [8469450.001]
  • [Cites] Br J Obstet Gynaecol. 1993 Apr;100(4):386-8 [8494842.001]
  • [Cites] J Ultrasound Med. 1993 May;12(5):275-80 [8345555.001]
  • [Cites] Breast Cancer Res Treat. 1993;26(1):101-5 [8400318.001]
  • [Cites] J Comput Assist Tomogr. 1994 Jan-Feb;18(1):77-86 [8282890.001]
  • [Cites] Lancet. 1994 Feb 19;343(8895):448-52 [7905955.001]
  • [Cites] Gynecol Oncol. 1994 Feb;52(2):185-90 [8314137.001]
  • [Cites] Am J Obstet Gynecol. 1994 Feb;170(2):447-51 [8116695.001]
  • [Cites] Br J Cancer. 1994 Mar;69(3):620-1 [8123501.001]
  • [Cites] Ultrasound Obstet Gynecol. 1995 Aug;6(2):116-20 [8535913.001]
  • [Cites] Radiology. 1995 Dec;197(3):603-8 [7480726.001]
  • [Cites] Radiology. 1996 Jul;200(1):105-10 [8657895.001]
  • (PMID = 18603495.001).
  • [ISSN] 1470-7330
  • [Journal-full-title] Cancer imaging : the official publication of the International Cancer Imaging Society
  • [ISO-abbreviation] Cancer Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 094ZI81Y45 / Tamoxifen
  • [Number-of-references] 95
  • [Other-IDs] NLM/ PMC2482152
  •  go-up   go-down






Advertisement